MONOAMINE-OXIDASE INHIBITORS AND THE CHEESE EFFECT

被引:134
作者
ANDERSON, MC [1 ]
HASAN, F [1 ]
MCCRODDEN, JM [1 ]
TIPTON, KF [1 ]
机构
[1] UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND
关键词
TYRAMINE; MONOAMINE OXIDASE-A (MAO-A); INTESTINE; CLORGYLINE; L-DEPRENYL; BROFAROMINE; MOCLOBEMIDE;
D O I
10.1007/BF00978365
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The behavior of inhibitors of monoamine oxidase-A (MAO-A) is considered in terms of the possibility of having an effective antidepressant that does not give rise to hypertensive interactions with dietary tyramine. Studies with punch-biopsy samples of human intestine and rat intestinal samples show MAO-A to be the predominant form of the enzyme in both species. Transport studies with everted rat intestinal preparations indicate that tyramine is extensively metabolized during transport through the intestine. Selective inhibition of MAO-A by clorgyline results in a large increase in the amount of unchanged tyramine transported, whereas selective inhibition of MAO-B with L-deprenyl (selegiline) has no significant effect. The behavior of reversible MAO-A inhibitors can significantly reduce, but not entirely eliminate, these effects on the intestinal metabolism of tyramine, but only if the inhibition is competitive in nature.
引用
收藏
页码:1145 / 1149
页数:5
相关论文
共 33 条
[1]   THE INHIBITION OF MONOAMINE-OXIDASE BY BROFAROMINE [J].
ANDERSON, MC ;
WALDMEIER, PC ;
TIPTON, KF .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (12) :1871-1877
[2]   TURNOVER OF BRAIN MONOAMINE-OXIDASE MEASURED INVIVO BY POSITRON EMISSION TOMOGRAPHY USING L-[C-11]DEPRENYL [J].
ARNETT, CD ;
FOWLER, JS ;
MACGREGOR, RR ;
SCHLYER, DJ ;
WOLF, AP ;
LANGSTROM, B ;
HALLDIN, C .
JOURNAL OF NEUROCHEMISTRY, 1987, 49 (02) :522-527
[3]   INTESTINAL METABOLISM OF TYRAMINE BY BOTH FORMS OF MONOAMINE-OXIDASE IN THE RAT [J].
BENEDETTI, MS ;
BOUCHER, T ;
CARLSSON, A ;
FOWLER, CJ .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (01) :47-52
[4]  
BIEK PR, 1988, PHARMACOL RES COMMUN, V20, P129
[5]  
BLACKWELL B, 1963, LANCET, V2, P849
[6]  
CALLINGHAM B A, 1985, British Journal of Pharmacology, V86, p553P
[7]  
CALLINGHAM BA, 1989, BR J PSYCHIAT S6, V115, P53
[8]  
Da Prada M, 1988, Pharmacol Res Commun, V20 Suppl 4, P21, DOI 10.1016/S0031-6989(88)80543-5
[9]  
DAPRADA M, 1990, J NEUR TR S, V29, P279
[10]  
DAPRADA M, 1988, J NEURAL TRANSM-SUPP, V26, P33